Analyst Rating Update on PTC Therapeutics (PTCT)

PTC Therapeutics (NASDAQ:PTCT) : The consensus on PTC Therapeutics (NASDAQ:PTCT) based on 8 analyst recommendation on the company stock is 2.25, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

PTC Therapeutics (NASDAQ:PTCT) : 6 investment research analysts covering PTC Therapeutics (NASDAQ:PTCT) have an average price target of $20 for the near short term. The highest target price given by the Brokerage Firm to the stock is $40 and the lowest target is $8 for the short term. Analysts expect the variance to be within $15.17 of the average price.

Company shares have received an average consensus rating of Hold for the current week

PTC Therapeutics (NASDAQ:PTCT): stock turned positive on Tuesday. Though the stock opened at $6.43, the bulls momentum made the stock top out at $6.9 level for the day. The stock recorded a low of $6.4175 and closed the trading day at $6.71, in the green by 7.19%. The total traded volume for the day was 956,388. The stock had closed at $6.26 in the previous days trading.

In an insider trading activity, Rothera Mark, officer (Chief Commercial Officer) of Ptc Therapeutics, Inc., had purchased 2,000 shares on March 3, 2016. The total value of the transaction was $12,460. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.